Linking immunomodulation and latency in alphaherpesvirus infection. Herpesviruses cause major diseases in humans and all domestic animal species. Latency forms a significant part of the evolutionary success of herpesviruses, by enabling transmission of the virus throughout the lifetime of the host. Our work has shown that an alphaherpesvirus protein can divert the host’s immune response to become more antibody-mediated and less T cell-mediated. This study explores the consequences of this immune ....Linking immunomodulation and latency in alphaherpesvirus infection. Herpesviruses cause major diseases in humans and all domestic animal species. Latency forms a significant part of the evolutionary success of herpesviruses, by enabling transmission of the virus throughout the lifetime of the host. Our work has shown that an alphaherpesvirus protein can divert the host’s immune response to become more antibody-mediated and less T cell-mediated. This study explores the consequences of this immune diversion, and examines whether this reduced T cell response enables the development of latent infections. Disrupting the virus-host balance by alterations to this conserved viral protein will enable novel approaches to controlling these economically significant viruses.Read moreRead less
Molecular basis of attenuation in live Mycoplasma vaccines. This proposal aims to use an innovative approach to address an urgent issue raised by the end users of an Australian-owned poultry vaccine with an extensive global market. Recently multiple mutations have been detected in the vaccine re-isolated from vaccinated birds in the field around the world. We will apply a combination of a novel technique for targeted mutagenesis, genome sequencing, and animal experimentations, to address the sig ....Molecular basis of attenuation in live Mycoplasma vaccines. This proposal aims to use an innovative approach to address an urgent issue raised by the end users of an Australian-owned poultry vaccine with an extensive global market. Recently multiple mutations have been detected in the vaccine re-isolated from vaccinated birds in the field around the world. We will apply a combination of a novel technique for targeted mutagenesis, genome sequencing, and animal experimentations, to address the significance of these mutations. Results will improve our understanding of the basis of attenuation of the vaccine, its mechanism of action, and provide commercial confidence in the safety of the vaccine, which is needed to support Australian Universities and Businesses, and the global poultry industry.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100020
Funder
Australian Research Council
Funding Amount
$520,000.00
Summary
Collaborative high bio-containment immunological research facility. Emerging infectious diseases are a serious threat to animals and humans, with most new human infections originating in animals. Our capacity to study these infections and their effects on the immune system is limited. This Facility will provide core equipment for analysis of immune responses to infection at the highest levels of bio-containment.
Multifunctional biodegradable nanoparticles for enhanced DNA vaccine delivery. DNA vaccine, which shows better immunological and economic merits than conventional vaccines, suffers clinical failure due to the difficulty of delivering intact DNA molecules to relevant cells. This project seeks to develop smart polymer nanospheres to protect the DNA molecules from premature degradation in order to improve its efficacy.
Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection. New drugs to treat T. cruzi infection are urgently needed, however their design has been hampered by an incomplete understanding of complex host-parasite interactions, inadequate in vitro and in vivo tools to rigorously define activity during drug discovery, and a poor appreciation of concentration/effect relationships. This project aims to develop new and much needed ....Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection. New drugs to treat T. cruzi infection are urgently needed, however their design has been hampered by an incomplete understanding of complex host-parasite interactions, inadequate in vitro and in vivo tools to rigorously define activity during drug discovery, and a poor appreciation of concentration/effect relationships. This project aims to develop new and much needed in vitro methods to better define the kinetic and dynamic activity of new drug candidates, and will provide a rational basis for translating this information into lengthy animal models of T. cruzi infection. The outcome aims to be rationally designed drug candidates that are available in a shorter period of time and are suitable for further development.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE120103084
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Targeting bacterial superbugs: novel approaches for optimisation of antibiotic combinations and resistance prevention. This project will elucidate the mechanistic basis to optimally combine available beta-lactam antibiotics to prevent resistance of gram-negative 'superbugs'. The interdisciplinary project will substantially contribute to solving the global crisis due to multidrug-resistant bacteria and inform the design of effective new antibiotics.
Targeting an impending global disaster: the mismatch between increasingly drug-resistant superbugs and development of new antibiotics. This project will develop much-needed novel antibiotics for treating infections caused by bacteria that are resistant to all current antibiotics. It will make a significant contribution to the global medical challenge of a shortage of new antibiotics.
Rational design of new drug candidates for the treatment of Trypanosoma cruzi infection. There is a serious shortage of safe and effective drugs to treat Chagas disease which is caused by a parasitic infection. This project aims to design and identify new drug candidates by defining the disposition profile within the body which is necessary to achieve a therapeutic effect.
Cellular and molecular networks controlling protective immunity. This research aims to understand how a handful of master-regulator genes act to program immune cells required for immune responses to microbes, vaccination and to prevent cancer. It will provide a fundamental advance in our understanding of immune cell development and impact strategies aimed at the prevention and treatment of pathogen infections.
Mathematical and statistical methods for modelling invivo pathogen dynamics. This project aims to develop mathematical models and Bayesian statistical methods that better capture how natural defence responses and drugs help control infection. When viruses (e.g. influenza) or parasites (e.g. malaria) invade the human body, they begin to replicate. To date, only simple mathematical models have been developed to capture these processes, and these models are not well formulated. This project will im ....Mathematical and statistical methods for modelling invivo pathogen dynamics. This project aims to develop mathematical models and Bayesian statistical methods that better capture how natural defence responses and drugs help control infection. When viruses (e.g. influenza) or parasites (e.g. malaria) invade the human body, they begin to replicate. To date, only simple mathematical models have been developed to capture these processes, and these models are not well formulated. This project will improve biomathematics and biostatistical algorithms for pathogen dynamics and is ultimately expected to benefit public health and clinical research aimed at alleviating the effect of infectious diseases on human health.Read moreRead less